Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States
November 25, 2024 07:05 ET
|
Clearside Biomedical, Inc.
- Commercial, Clinical and Regulatory Expertise Establish Clearside as the Leader in Suprachoroidal Delivery - - Multiple Events at Asia-Pacific Vitreo-Retina Society Congress Highlighting...
Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024 16:05 ET
|
Clearside Biomedical, Inc.
- Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes - - Positive Topline Results Support Advancing CLS-AX to Phase 3 Targeting a...
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
November 06, 2024 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors
November 04, 2024 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024
October 31, 2024 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting
October 22, 2024 07:05 ET
|
Clearside Biomedical, Inc.
- CLS-AX Phase 3 Ready Based on Positive Phase 2b Topline Data in Wet AMD - - Differentiated Profile for CLS-AX Targeting Flexible Dosing Similar to a Biologic with the Potential Extended Duration of...
Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes
October 09, 2024 06:30 ET
|
Clearside Biomedical, Inc.
- Maintained Stable Visual Acuity and Anatomical Control Over 9 Months - - Positive Safety Profile with No Ocular or Treatment-Related Serious Adverse Events - - 67% of CLS-AX Participants Did Not...
Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
August 27, 2024 07:05 ET
|
Clearside Biomedical, Inc.
- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s Proprietary SCS Microinjector® - - Topline Data Expected to be Reported During the Week of October...
Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024 16:05 ET
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 - - ODYSSEY Safety Review Committee Recommends Trial Continue as Planned with no Serious Adverse...
Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 08, 2024 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...